TGTX is having a rough start in 2015. The stock is down
over 22% from its highs at the beginning of this year.
However I am holding my position because I cannot find a good reason for this price-drop and I am not convinced it has broken its positive price-movement trend.
TGTX’s current price is running at about its 75-day SMA (simple moving average) where it’s been several other times over the past 9 months so its price may just be trading at a low and presenting a good buying opportunity.
If TGTX's price moves beneath its SMA (75) this may signal a change to negative for its market sentiment and its price movement. In that case I will look to adjust my holding for the short-term.
The stock’s medium and longer term prospects
still look great.
They kicked-off enrollments in their first Phase 3 clinical trial and are on track to deliver a bunch of clinical trial updates this year.
TGTX also got an endorsement from Cramer
on his Mad-Money show last week which shows their promising drugs are starting
to get noticed. You can see the interview at this link https://www.youtube.com/watch?v=Pp9aegwcsMQ
Below I have updated TGTX’s clinical
activities for 2015:
* Started enrollment in their first Phase3 combo trial of
TG-1101 plus Imbruvica versus Imbruvica alone for treating high-risk CLL.
Enrollment completion in Q3 2016.
Enrollment completion in Q3 2016.
* Register Phase3 trial for combo TG-1101 plus TGR-1202 for treating relapsed NHL & CLL.
* Register Phase3 trial for TGR-1202 as a single agent for treating relapsed hematologic malignancies.
* Present Phase I/II trial results of single Agent TG-1101 in Relapsed/Refractory NHL & CLL.
EPC (Estimated Primary Completion Date) Feb 2015
* Present trial results in Q2 2015 of combo TGR-1202 plus Gazyva plus chlorambucil in patients with previously untreated CLL.
* Present trial results in Q2 2015 for combo TGR-1202 plus brentuximab vedotinin for relapsed Hodgkin’s Lymphoma.
* Present Phase I trial results for combo TG-1101 plus TGR-1202 for Relapsed/Refractory NHL & CLL. Also evaluated in this study is the triple combination of TG-1101 plus TGR-1202 plus ibrutinib (IMBRUVICA). EPC Date Jun 2015
* Present Phase2 trial results for combo TG-1101 plus Imbruvica for Relapsed/Refractory MCL & CLL. EPC Date Jun 2015
* Enter into clinical phase IRAK-4 inhibitor in Q3 2015.
* Present trial results for single agent TGR-1202 in patients with relapsed/refractory Hematologic Malignancies. EPC Date Aug 2015
* Begin new combo trial of TGR-1202 & Imbruvica for patients with CLL or MCL.
EPC Feb 2018
Disclosure - I trade TGTX at Marketocracy.com & I only hold long positions
